Updates are available Correction dated 2020-07-29
Click to view Correction: https://doi.org/10.1038/s41586-020-2583-3
-
Authors
Qian, Hao
Kang, Xinjiang
Hu, Jing
Zhang, Dongyang https://orcid.org/0000-0003-2365-4763
Liang, Zhengyu
Meng, Fan
Zhang, Xuan
Xue, Yuanchao https://orcid.org/0000-0002-8113-2333
Maimon, Roy
Dowdy, Steven F.
Devaraj, Neal K. https://orcid.org/0000-0002-8033-9973
Zhou, Zhuan https://orcid.org/0000-0001-9048-6638
Mobley, William C.
Cleveland, Don W. https://orcid.org/0000-0002-1934-3682
Fu, Xiang-Dong https://orcid.org/0000-0001-5499-8732
- License Information
-
More Information
Article History
Received: 12 November 2018
Accepted: 13 May 2020
First Online: 24 June 2020
Change Date: 29 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-020-2583-3
Competing interests
: X.-D.F. is a founder of CurePharma. The University of California, San Diego has filed a patent application on neuronal reprogramming induced by inactivating PTB by any means for treatment of neurological disorders.
